TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7679164

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg, three times daily for 3 days)
Number of subjects: 8
Study: 27993

Group type: EXPERIMENTAL
Intervention: ketamine/flunitrazepam
Number of subjects: 150

Group type: COMPARATOR
Intervention: ketamine/diazepam
Number of subjects: 150

Group type: COMPARATOR
Intervention: ketamine/placebo
Number of subjects: 150
Study: 30241951

Group type: EXPERIMENTAL
Intervention: Combined low-frequency stimulation of the substantia nigra pars reticulata (LF-SNr) and high-frequency stimulation of the subthalamic nucleus (HF-STN)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-frequency stimulation of the subthalamic nucleus (HF-STN)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-frequency stimulation of the substantia nigra pars reticulata (LF-SNr)
Number of subjects: 6
Study: 28468607

Group type: EXPERIMENTAL
Intervention: Group LIA (Local Infiltration Analgesia) with 30 mL saline, ropivacaine 2 mg/mL (300 mg), ketorolac 30 mg, adrenaline 0.5 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Group FNB (Femoral Nerve Block) with 30 mL ropivacaine 7.5 mg/mL (225 mg) and 151.5 mL saline
Number of subjects: 56
Study: 26073387

Group type: EXPERIMENTAL
Intervention: ETC-1002 60 mg daily (increased to 120 mg, 180 mg, and 240 mg at 2-week intervals)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ETC-1002
Number of subjects: 56

Group type: COMPARATOR
Intervention: ETC-1002 and Placebo
Number of subjects: 56
Study: 24173676

Group type: EXPERIMENTAL
Intervention: 25 ml 0.5% levobupivacaine plus 4 mg dexamethasone (group 1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 25 ml 0.5% levobupivacaine plus 1 ml saline (group 2)
Number of subjects: 70
Study: 22679695

Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (0.3 mg) or bevacizumab (0.625 mg/0.025 ml) with conventional diode laser photocoagulation (Group A)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Laser therapy combined with cryotherapy (Group B)
Number of subjects: 87
Study: 19041224

Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10) (50 mg/d), vitamin E (50 mg/d), and selenium (48 mug/d)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (soy lecithin)
Number of subjects: 58
Study: 18158596

Group type: EXPERIMENTAL
Intervention: FDT software version 3.0
Number of subjects: 100

Group type: COMPARATOR
Intervention: FDT software version 2.6
Number of subjects: 100
Study: 12817656

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: CIMT
Number of subjects: 4
Study: 11068970

Group type: COMPARATOR
Intervention: Mother program
Number of subjects: 240

Group type: COMPARATOR
Intervention: Dual-component program
Number of subjects: 240
Study: 8633396

Group type: EXPERIMENTAL
Intervention: Self-administration of the International Prostate Symptom Score (IPSS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Physician administration of the International Prostate Symptom Score (IPSS)
Number of subjects: 64
Study: 1443066

Group type: EXPERIMENTAL
Intervention: Multicomponent support-group program for caregivers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 3964987

Group type: EXPERIMENTAL
Intervention: Repeated dietary records
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Highly supplemented nutrients (iron, vitamin C, B vitamins)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Repeated records measuring dietary intake
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Repeated records measuring total intake
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Dietary records per individual
Number of subjects: 151
Study: 30785935

Group type: EXPERIMENTAL
Intervention: 2009 SIMCE outcomes
Number of subjects: 1353
Study: 27607734

Group type: EXPERIMENTAL
Intervention: 16-Gy boost after BCS and 50-Gy WBI
Number of subjects: 1616

Group type: COMPARATOR
Intervention: No boost after BCS and 50-Gy WBI
Number of subjects: 1616
Study: 26004866

Group type: EXPERIMENTAL
Intervention: Microsurgical spermatic cord denervation
Number of subjects: 50
Study: 23929061

Group type: EXPERIMENTAL
Intervention: Low-cost cognitive-behavioral motivational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21112185

Group type: EXPERIMENTAL
Intervention: Bupropion SR and a psychoeducational intervention for smoking cessation
Number of subjects: 0
Study: 19915217

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (2000 mg per day)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Ezetimibe (10 mg per day)
Number of subjects: 208
Study: 17309463

Group type: EXPERIMENTAL
Intervention: Piroxicam gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 50
Study: 15492151

Group type: EXPERIMENTAL
Intervention: Mesh plug repair
Number of subjects: 334

Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 334

Group type: COMPARATOR
Intervention: Prolene Hernia System
Number of subjects: 334
Study: 11736880

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Amlodipine (5 mg)
Number of subjects: 145
Study: 9253326

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE; 250 mg, i.m., every 21 days)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Single s.c. implantation of 1200 mg crystalline testosterone (TPEL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Baseline serum OB levels in hypogonadal men
Number of subjects: 22
Study: 8322988

Group type: EXPERIMENTAL
Intervention: Peribulbar blockade
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Retrobulbar blockade
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 30
Study: 3531248

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 104

Group type: COMPARATOR
Intervention: Methysergide
Number of subjects: 104
Study: 31225647

Group type: EXPERIMENTAL
Intervention: BoNT‐A plus occupational therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 20
Study: 31501165

Group type: EXPERIMENTAL
Intervention: Standard care with manual and GP follow-up
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Standard care with manual and stroke nurse follow-up
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 40
Study: 28436117

Group type: EXPERIMENTAL
Intervention: Paricalcitol 2 μg/day
Number of subjects: 77
Study: 26024502

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sham remote ischemic preconditioning (control)
Number of subjects: 240
Study: 23161160

Group type: EXPERIMENTAL
Intervention: Speed of the whirligig (increased speed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speed of the dancer (increased speed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived animacy of the dancer
Number of subjects: 0
Study: 21745059

Group type: EXPERIMENTAL
Intervention: Peyton's Four-Step Approach (IG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard instruction (CG)
Number of subjects: 34
Study: 19771284

Group type: EXPERIMENTAL
Intervention: Whole-body vibration and resistance training
Number of subjects: 13

Group type: COMPARATOR
Intervention: Resistance training only
Number of subjects: 13
Study: 16948806

Group type: EXPERIMENTAL
Intervention: Tapering down omeprazole for three weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Constant dosage of omeprazole for three weeks
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Overall discontinuation of PPIs
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: GERD patients
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Serum gastrin levels
Number of subjects: 97
Study: 15191594

Group type: EXPERIMENTAL
Intervention: Image analysis method for plaque measurement
Number of subjects: 40
Study: 10899492

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 50 mg/d for 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9476268

Group type: EXPERIMENTAL
Intervention: Baseline radiological features including distribution of joint space loss, subchondral bone production, and severity of joint space loss
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Joint space width measurement
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Radiographic progression
Number of subjects: 463
Study: 8177098

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (20 micrograms ethinyl estradiol and 150 micrograms desogestrel) for 6 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 59
Study: 3653128

Group type: EXPERIMENTAL
Intervention: Oestrogen therapy (polyestradiol phosphate 80 mg i.m. per month + 150 micrograms ethinylestradiol p.o. per day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oestrogen therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 100
Study: 28301911

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) treatment
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Platelet function analysis using ASPItest and TRAPtest
Number of subjects: 400
Study: 27940956

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg subcutaneously before intervention, followed by 0.6 mg for 2 days, 1.2 mg for 2 days, and 1.8 mg for 3 days)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 26575873

Group type: COMPARATOR
Intervention: Aminophylline 1 mg/kg, once every 8 hours
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aminophylline 2 mg/kg, once every 8 hours
Number of subjects: 40
Study: 23725303

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Adapalene 0.3%
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05%
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 21504340

Group type: EXPERIMENTAL
Intervention: Combined therapy of oral micronized progesterone capsules (Utrogestan 3 x 100 mg) and vaginal progesterone gel (Crinone 8%, 90 mg daily)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Progesterone monotherapy (vaginal progesterone gel, Crinone 8%, 90 mg daily)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 370

Group type: COMPARATOR
Intervention: Progesterone monotherapy
Number of subjects: 370
Study: 18425621

Group type: EXPERIMENTAL
Intervention: Thalidomide (THL) in combination with riluzole
Number of subjects: 37

Group type: COMPARATOR
Intervention: Riluzole alone
Number of subjects: 37
Study: 16495259

Group type: EXPERIMENTAL
Intervention: Artesunate suppositories (8 to 16 mg/kg at 0 and 12 h, then daily)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Intramuscular artemether (3.2 mg/kg at 0 h, then 1.6 mg/kg daily)
Number of subjects: 79
Study: 14511846

Group type: EXPERIMENTAL
Intervention: Lercanidipine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacidipine 2 mg
Number of subjects: 0
Study: 11045860

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 103)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (n = 102)
Number of subjects: 205
Study: 8733987

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol nasal inhaler (220 micrograms/d)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 2317442

Group type: EXPERIMENTAL
Intervention: Inderal LA 80 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inderal LA 160 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inderal LA 320 mg
Number of subjects: 12
Study: 7000166

Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 0
Study: 31137994

Group type: EXPERIMENTAL
Intervention: Combined treatment with LP Nd:YAG laser and 10% KOH application
Number of subjects: 38

Group type: COMPARATOR
Intervention: LP Nd:YAG laser therapy only
Number of subjects: 38
Study: 31124397

Group type: EXPERIMENTAL
Intervention: Dance/movement training (DMT; n=12)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AT; n=14)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait list (WL; n=14)
Number of subjects: 40
Study: 28081824

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 4385

Group type: COMPARATOR
Intervention: OxPL-apoB
Number of subjects: 4385
Study: 25869983

Group type: EXPERIMENTAL
Intervention: Modified osteotomy design (angled oblique buccal bone cut)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional osteotomy design
Number of subjects: 28
Study: 22434336

Group type: EXPERIMENTAL
Intervention: Listening to the same initial piece during follow-up sessions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Listening to the same initial piece during follow-up sessions (distraction condition)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Listening to nonmusical sounds after learning the piece
Number of subjects: 36
Study: 22152087

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 7) that participated in supine resistance and aerobic exercise training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (n = 8) that remained physically inactive
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups (exercise and control)
Number of subjects: 15
Study: 20384011

Group type: EXPERIMENTAL
Intervention: Anxious condition (high-threat)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Calm condition (low-threat)
Number of subjects: 14
Study: 16519641

Group type: EXPERIMENTAL
Intervention: Standard postoperative care plus immediate use of chewing gum
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard postoperative care (control group)
Number of subjects: 38
Study: 14521655

Group type: EXPERIMENTAL
Intervention: Distal RV Coil Position
Number of subjects: 31

Group type: COMPARATOR
Intervention: Proximal RV Coil Position
Number of subjects: 31
Study: 10648268

Group type: EXPERIMENTAL
Intervention: Vitamin cocktail containing 272 mg vitamin C, 31 mg all‐rac‐alpha‐tocopheryl acetate, and 400 microg folic acid
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 9144686

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles (6 months)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Standard treatment with oral cyclophosphamide (100 mg/m2/d days 1 through 14), intravenous methotrexate (40 mg/m2 days 1 and 8), intravenous 5-fluorouracil (600 mg/m2 days 1 and 8), and oral prednisolone (40 mg/m2/d days 1 through 14) for six cycles (6 months)
Number of subjects: 208
Study: 8129554

Group type: EXPERIMENTAL
Intervention: Hydroquinidine (600 mg per 24 hours)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Quinidine (1100 mg)
Number of subjects: 14
Study: 3315608

Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 86
Study: 29023825

Group type: EXPERIMENTAL
Intervention: GenIce tool for generating hydrogen-disordered ice structures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GenIce tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GenIce algorithm
Number of subjects: 0
Study: 27764842

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 83
Study: 24702733

Group type: EXPERIMENTAL
Intervention: Monotherapy with metformin
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Metformin with rosiglitazone
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Metformin with intensive lifestyle intervention
Number of subjects: 699

Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 699
Study: 23030572

Group type: EXPERIMENTAL
Intervention: Higher text cohesion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lower text cohesion
Number of subjects: 42
Study: 20446889

Group type: EXPERIMENTAL
Intervention: Vitamin D intake (average daily intake 144.8 IU, SD 84.6)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Calcium intake (average daily intake 966.4 mg, SD 273.7)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Vitamin D supplementation
Number of subjects: 207

Group type: COMPARATOR
Intervention: Osteoporosis medications
Number of subjects: 207
Study: 18611063

Group type: EXPERIMENTAL
Intervention: Intravenous lanthanum chloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral lanthanum carbonate (3000 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral lanthanum carbonate
Number of subjects: 0
Study: 16182831

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cyclosporine-ME
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Tacrolimus and Cyclosporine-ME
Number of subjects: 205
Study: 12851624

Group type: EXPERIMENTAL
Intervention: AMP579 (60 mcg/kg)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: AMP579 (other doses)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: AMP579 (all doses)
Number of subjects: 311
Study: 11601221

Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG) combined with cyclosporine A (CsA) - Intensive immunosuppressive therapy (IIST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antilymphocyte globulin (ALG) alone - Non-intensive immunosuppressive therapy (NIIST)
Number of subjects: 0
Study: 8678273

Group type: EXPERIMENTAL
Intervention: Pressure-controlled mechanical ventilation with PEEP and permissive hypercapnia, body position changes, inhalation of nitric oxide.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO) as an additional therapeutic option if other procedures fail.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional standard treatment (not specified in detail).
Number of subjects: 0
Study: 1411294

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bismuth compound (120 mg four times daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 3847874

Group type: EXPERIMENTAL
Intervention: Behaviorally self-blaming rape victims (present self-blame)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Non-behaviorally self-blaming rape victims (absent self-blame)
Number of subjects: 144
Study: 29724622

Group type: COMPARATOR
Intervention: Polyglactin 910 6‐0 suture (Vicryl, Ethicon, Johnson and Johnson Ltd., India)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Polydioxanone 6‐0 suture (PDS II, Ethicon, Johnson and Johnson Ltd., India)
Number of subjects: 60
Study: 27550310

Group type: EXPERIMENTAL
Intervention: 4 cm coverage size
Number of subjects: 63

Group type: COMPARATOR
Intervention: 8 cm coverage size
Number of subjects: 63
Study: 24680768

Group type: EXPERIMENTAL
Intervention: Tacrolimus administered via site-specific radiolabeled delivery capsule (1 mg in 2 mg/mL solution)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tacrolimus administered via site-specific radiolabeled delivery capsule
Number of subjects: 6
Study: 22739083

Group type: EXPERIMENTAL
Intervention: Dietary counseling by registered dietitians during ordinary diet and delivered meal period
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Calorie-controlled meals during ordinary diet and delivered meal period
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ordinary diet without dietary counseling
Number of subjects: 200

Group type: COMPARATOR
Intervention: Calorie-controlled meals without dietary counseling
Number of subjects: 200
Study: 20199989

Group type: EXPERIMENTAL
Intervention: Family nutritional support
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (antiretroviral treatment only)
Number of subjects: 180
Study: 18279690

Group type: EXPERIMENTAL
Intervention: Spermicides containing nonoxynol-9 (N-9)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Three gels containing different doses of N-9
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Three different formulations containing the same dose of N-9
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Different formulations and doses of spermicides containing N-9
Number of subjects: 640
Study: 16167911

Group type: EXPERIMENTAL
Intervention: 25 mg of levobupivacaine
Number of subjects: 437

Group type: COMPARATOR
Intervention: 25 mg of racemic bupivacaine
Number of subjects: 437
Study: 12759801

Group type: EXPERIMENTAL
Intervention: Tryptophan augmented (T+)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Tryptophan depleted (T-)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: T+
Number of subjects: 96

Group type: COMPARATOR
Intervention: T-
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Baseline plasma tryptophan
Number of subjects: 96
Study: 10327295

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT) 200 IU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal salmon calcitonin (SCT)
Number of subjects: 0
Study: 8904258

Group type: EXPERIMENTAL
Intervention: 1 mg/kg lidocaine (LD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg/kg meperidine (MP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 25 mu g fentanyl (FN)
Number of subjects: 30
Study: 2003893

Group type: EXPERIMENTAL
Intervention: Postoperative diflunisal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Postoperative placebo
Number of subjects: 24
Study: 6280796

Group type: EXPERIMENTAL
Intervention: Polychemotherapy with cyclophosphamid + 5‐FU + MTX + vinblastin
Number of subjects: 859

Group type: COMPARATOR
Intervention: New designed intermittent polychemotherapy-schedule (alternating cyclophosphamid + CCNU + MTX, then cyclophosphamid + adriamycin + vincristin, then ifosfamid + VP‐16) followed by radiation therapy
Number of subjects: 859
Study: 30721171

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both LASIK and SMILE
Number of subjects: 21
Study: 30103334

Group type: EXPERIMENTAL
Intervention: Cogmed Adaptive CCT
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-Adaptive CCT (active control)
Number of subjects: 82